Benjamin Looker, General Counsel of Esperion Therapeutics ($ESPR), made six open market sales of company shares over the past year, totaling $58,500. His latest sale occurred on January 20, 2026. These transactions rank 10,225th among 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.4 transactions per insider. Looker made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | Chief Legal Officer | S | Common Stock | 5708 | $2.70 | 679,348.0000 | 239,063,437 | 0.83% | 0.00% |
| March 13, 2026 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | Chief Legal Officer | A | Stock Option (right to buy) | 269230 | $0.00 | 269,230.0000 | 239,063,437 | 9999.99% | 0.11% |
| March 13, 2026 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | Chief Legal Officer | A | Common Stock | 300840 | $0.00 | 685,056.0000 | 239,063,437 | 78.30% | 0.13% |
| Jan. 20, 2026 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | S | Common Stock | 1689 | $2.88 | 384,216.0000 | 239,063,437 | 0.44% | 0.00% |
| Dec. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | S | Common Stock | 6517 | $3.67 | 385,905.0000 | 239,063,437 | 1.66% | 0.00% |
| Oct. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | S | Common Stock | 1248 | $2.62 | 392,422.0000 | 197,848,886 | 0.32% | 0.00% |
| Sept. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | S | Common Stock | 6267 | $2.80 | 393,670.0000 | 197,848,886 | 1.57% | 0.00% |
| July 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | S | Common Stock | 1304 | $1.13 | 399,937.0000 | 197,848,886 | 0.32% | 0.00% |
| June 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | S | Common Stock | 6422 | $1.15 | 401,241.0000 | 197,848,886 | 1.58% | 0.00% |
| March 14, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | A | Stock Option (right to buy) | 201000 | $0.00 | 201,000.0000 | 197,848,886 | 9999.99% | 0.10% |
| March 14, 2025 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | A | Common Stock | 224000 | $0.00 | 407,663.0000 | 197,848,886 | 121.96% | 0.11% |
| March 14, 2024 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| March 14, 2024 | Esperion Therapeutics, Inc. | $ESPR | Looker Benjamin | General Counsel | A | Common Stock | 100000 | $0.00 | 183,663.0000 | 0 | 119.53% | 0.00% |